DAHUA-TECHNOLOGY
13.12.2021 14:47:04 CET | Business Wire | Press release
With rapid global urbanization and seemingly perpetual increase in vehicle ownership every year, improving traffic safety and efficiency has become a tough challenge. According to the assessment of international ITS organizations, an effective intelligent transportation system can help reduce traffic congestion and accidents by 20% and traffic delays by 25%. The Dahua Smart Traffic Management Solution , for example, has been applied in various countries to alleviate traffic problems and provide better driving and commuting experience. Equipped with AI, ANPR, image fusion, AR and robust communication technologies, the Dahua Smart Traffic Management Solution can accurately detect traffic violations and optimize signal control timing based on real-time data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005357/en/
Traffic enforcement is one of the key focuses of this solution. By deploying traffic cameras with ANPR (e.g. ITC952-AU3F-LZF1640 model), traffic violations such as overspeeding, distracted driving, red light violation, unfastened seatbelt, illegal lane changing, etc. can be accurately detected. It supports recognition of number plates from 100 countries and allows algorithm integration with multiple countries. In addition, this Dahua solution also offers an AR Panoramic Platform that is connected to all frontend devices, and presents new labeling display system. It enables traffic operators to respond to traffic alerts and situations in time.
Another aspect of this solution involves signal control timing optimization based on real-time traffic flow . Powered by a lane-level traffic flow detection system, this solution can cover large scenes to detect multiple parameters such as lane flow, occupancy rate, queue length, traffic density, etc. With real-time data captured and analyzed, the traffic lights will automatically switch based on the time of the day and actual road traffic conditions, effectively mitigating urban traffic congestions. Green wave can be carried out during certain times for quick passage of vehicles. Also, these collected traffic data can help city operators in optimizing road network planning.
Meeting the numerous requirements of present-day traffic management, this solution has been applied in various countries and regions around the globe, including Serbia, Mongolia, Indonesia, and Saudi Arabia. One notable example of its effective implementation is in a country in Central Asia. It was deployed at an intersection where vehicle traffic reaches 170,000-250,000 cars per day. It significantly reduced waiting time, improved traffic efficiency by about 25%, helped enhance traffic flow, and lessened the effects of traffic congestion in the surrounding areas of the intersection.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005357/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
